About The Clav Stack

theclavstack.com is a protocol-focused editorial site. It documents one thing: the 5-layer peptide stack that the figure publishing under the name Clavicular has described in detail across his public posts since the TRIUMPH-4 retatrutide readout in late 2025. The site does not cover peptides outside that stack, does not publish protocols beyond what Clavicular has personally described, and does not invent a layer or substitution.

That narrowness is deliberate. The site only addresses the protocol as a system: what each layer does, why Clavicular sequenced them in this order, and where the published trial data does and doesn’t support each choice. We do not run product reviews of peptides outside the stack, do not run a vendor catalogue, and do not chase ranking opportunities in adjacent compounds. If you came here looking for any of those, this isn’t the site for it.

What we cover, and what we don’t

The eleven compounds documented here are the full stack: Retatrutide (in 4 vial sizes), BPC-157, GHK-CU, SNAP-8, CJC-1295, Ipamorelin, TB-500, Epithalon, and Bacteriostatic Water. We do not write about tirzepatide, semaglutide, MOTS-C, melanotan, or any of the other compounds peptide affiliate sites typically pad their catalogues with — even the ones that would be easy ranking wins. If Clavicular hasn’t personally protocolised a compound, it isn’t on this site.

Sourcing

All affiliate links resolve to Phiogen, a research-compound supplier based in Reykjavík, Iceland that publishes per-lot HPLC purity data. Phiogen is the supplier Clavicular has named in his own posts. We do not link to vendors who don’t publish lot-level analytical data, and we do not link to vendors who weren’t on Clavicular’s own list — even when their commission terms are better.

Trial citations

Where a layer rests on a clinical trial — Retatrutide on the Phase 2 Eli Lilly readout (NEJM 2023) and the TRIUMPH programme; CJC-1295/Ipamorelin on the long-running GH-secretagogue literature; BPC-157 on the preclinical corpus that runs to 36-plus studies — the trial is named, dated, and (where a public DOI exists) linked. Where evidence is preclinical-only or anecdotal, we say so on the page rather than smoothing it over.

Editor

The editor of theclavstack.com is Jeff Ferguson, an independent editor. Jeff is not a clinician, not a biochemist, and does not present himself as either. The editorial role here is reading the trial reports as they come out, reading what Clavicular publishes, and writing up the gap between what the data supports and what protocol copy on competing sites typically claims. Anything on this site that needs clinical interpretation belongs in front of a clinician, not on a peptide-research website.

Editorial corrections, factual challenges, and trial-citation disputes are welcomed and processed on a rolling basis. Reach the editor through the contact methods in the site footer.